Current challenges in the discovery of novel antibacterials from microbial natural products

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 3, 2012, Pages 189-204

  Genilloud, Olga ^a  

^a Health Sciences Technology Park   (Spain)

Author keywords

Antibiotic; Fermentation; Microbial diversity; Microbial natural products; Multiresistance; Patents

Indexed keywords

AMINOGLYCOSIDE; CB 183 315; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FIDAXOMICIN; GSK 1322322; GSQ 83698; KIBDELOMYCIN; LYSOBACTIN; MACROLIDE; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; NAB 739; NAI 107; NATURAL PRODUCT; NVB 302; OP 1118; PENICILLIN DERIVATIVE; PHILIPIMYCIN; PLATENCIN; PLAZOMICIN; PROPIOLACTONE; RETAPAMULIN; TELAVANCIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BIOSYNTHESIS; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; EPIGENETICS; GENOMICS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IC 50; MEMBRANE DEPOLARIZATION; MICROBIAL DIVERSITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PATENT; PHARMACOPHORE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 84870172863     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112803521968     Document Type: Article

References (140)

1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008; 197: 1079-81.
2. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
3. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64: i29-i36.
4. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 71-109.
5. European Centre for Disease Prevention and Control/European Medicines Agency. European Centre for Disease Prevention and Control/European Medicines Agency Joint Technical Report. the Bacterial Challenge: Time to React/http://www.emea.europa.eu/pdfs/human/antimicrobial_resistance/EMEA-576176-2009.pdfS.
6. Infectious Diseases Society of America. The 10_'20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-83.
7. Hamad B. The antibiotics market. Nat Rev Drug Discov 2010; 9: 675-6.
8. Newman DJ, Cragg GM. 2012 Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311-35.
9. Feher M, Schmidt JM. Property distributions: Differences between drugs, natural products and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003; 43: 218-27.
10. Clardy J, Walsh C. Lessons from natural molecules. Nature 2004; 432: 829-37.
11. Butler MS, Cooper MA. Antibiotics in the pipeline in 2011. J. Antibiotics 2011; 64: 413-25.
12. Boldi AM. Libraries from natural product-like scaffolds. Curr Opin Chem Biol 2004; 8: 281-6.
13. Haustedt LO, Mang C, Siems K, Schiewe H. Rational approaches to natural-product-based drug design. Curr Opin Drug Discov Devel 2006; 9: 445-62.
14. Li JW-H, Verderas JC. Drug discovery and natural products: End of an era or an endless frontier? Science 2009; 325: 161-5.
15. Harvey AL. Natural products in drug discovery. Drug Discov Today 2008; 13: 894.
16. Moellering RC. Discovering new antimicrobial agents. Int J Antimicrob Agents 2011; 37: 2-9.
17. Fishbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 2009; 325:1089-93.
18. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st centurya clinical super-challenge. N Engl J Med 2009; 360: 439-43.
19. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 2727-34.
20. Zhong P, Shortridge VD. The role of efflux in macrolide resistance. Drug Resistance Updates 2000; 3: 325-29.
21. Or YS, Clark RF, Wang S, Chu DTW, Nilius AM, Flamm RK, et al. Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. J Med Chem 2000, 43: 1045-9.
22. Champney, WS, Tober, CL. Structure-activity relationships for six ketolide antibiotics. Curr Microbiol 2001; 42: 203-10.
23. Coronelli C, White RJ, Lancini GC, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes. Isolation, chemical, biological and biochemical characterization. J Antibiot 1975; 28: 253-59.
24. Liang, C.-H., Duffield, J., Romero, A., Chiu, Y.-H., Rabuka, D., Yao, S., Sucheck, S., Marby, K., Shue, Y.-K., Ichikawa, Y., Hwang, C.-K. Novel antibacterial agents. WO2004080391A2 (2004) & US 7601695B2 (2009).
25. Duffield, J., Hwang, C.-K., Ichikawa, Y., Shue, Y.-K. Antibacterial agents. US8012943 (2011).
26. Babakhani F, Gomez A, Robert N, and Sears P. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011; 60: 1213-7.
27. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004; 48: 4430-4.
28. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolaños M. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004; 48: 4898-902.
29. Lancaster JW, Matthews SJ. Fidaxomicin: The newest addition to the armamentarium against Clostridium difficile infections. Clin Ther 2012; 34: 1-13.
30. Barrett, J.F., Herath, K., Jayasuriya, H., Masurekar, P., Ondeyka, J.G., Singh, S.B., Zhang, C. Antibiotic compound. WO2006086012A2 (2006).
31. Jayasuriya H, Herath K, Ondeyka JG, Zhang C, Zink DL, Brower M, et al. Isolation and structure elucidation of thiazomycin-a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. J Antibiot 2007; 60: 554-64.
32. Singh SB, Occi J, Jayasuriya H, Herath K, Motyl M, Dorso K, et al. Antibacterial evaluations of thiazomycin-a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. J Antibiot (Tokyo) 2007; 60: 565-71.
33. Zhang C, Zink DL, Ushio M, Burgess B, Onishi R, Masurekar P, et al. Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. Bioorg Med Chem 2008; 16: 8818-23.
34. Zhang C, Herath K, Jayasuriya H, Ondeyka JG, Zink DL, Occi J, et al. Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa J Nat Prod 2009; 72: 841-7.
35. Carnicer, A.B., Genilloud, O., Singh, S.B., Vicente, F., Zhang, C., Zink, D.L. Antibiotic compound. WO2008024285A2 (2008).
36. Zhang C, Occi J, Masurekar P, Barrett JF, Zink DL, Smith S, et al. Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347. J Am Chem Soc 2008; 130: 12102-10.
37. Mahajan, G.B., George, S., Ranadive, P., Mishra, P., Eyyammadichiyil, S., Panshikar, R., Sawant, S., Krishna, S., Sivakumar, M., Pari, K., Thomas, B., Patel, Z., Vishwakarma, R., Naik, G. Novel antibacterial compounds. WO2007119201A2 (2007).
38. Parker WL, Rathnum ML, Liu WC. SQ 26,517-A Beta-lactone Produced by a Bacillus Species. J Antibiot 1982; 35: 900-2.
39. Sieber, S.A., Mainsach, T.B. Beta lactones as antibacterial agents. US20110196027 (2011).
40. Wang C, Li M, Dong D, Wang J, Ren J, Otto M, et al. Role of ClpP in biofilm formation and virulence of Staphylococcus epidermidis. Microbes and Infection 2007; 9: 1376-83.
41. Von Nussbaum, F., Brunner, N., Anlauf, S., Endermann, R., Fürstner, C., Hartmann, E., Köbberling, J., Ragot, J., Schiffer, G., Schuhmacher, J., Svenstrup, N., Telser, J., Bruening, M.-A. Acylated nonadepsipeptides. US7368424 (2008).
42. Von Nussbaum, F., Beck, H., Brunner, N., Endermann, R., Koebberling, J., Ragot, J., Telser, J., Schuhmacher, J., Anlauf, S., Cancho-grande, Y., Greschat, S., Militzer, H.-C., Schiffer, G. Lysobactin amides. US8076285 (2011).
43. Boakes, S., Cortes, B.J., Dawson, M.J. Lantibiotic biosynthetic genes clusters from A. garbadinensis and A. liguriae. US7989416 (2011).
44. Seibert, G., Vértesy, L., Wink, J., Winkler, I., Broenstrup, M., Hoffmann, H., Guehring, H., Toti, L., Süssmuth, R., Sheldrick, G., George, M., Meindl, K. Novel peptides from Actinomadura namibiensis. US20090298904 (2009).
45. Meindl K, Schmiederer T, Schneider K, Reicke A, Butz D, Keller S, et al. Labyrinthopeptins: A new class of carbacyclic lantibiotics. Angewandte Chem Int Edithttp://onlinelibrary.wiley.com/doi/10.1002/anie.v49:6/issuetoc 2010; 49: 1151-4.
46. Jabés D, Brunati C, Candiani G, Riva S, Romanó G, Donadio S. Efficacy of the new antibiotic NAI-107 in experimental infections induced by MDR Gram-positive pathogens. Antimicrob Agents Chemother 2011; 55: 1671-6.
47. Snydman DR, Jacobus NV, McDermott LA. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other gram-positive aerobic and anaerobic intestinal pathogens Antimicrob Agents Chemother 2012; 56: 3448-52.
48. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 2000; 39: 1256-62.
49. Lofland D, Difuntorum S, Waller A, Clements, Weaver MK, Karlowsky JA, et al. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother 2004; 53: 664-68.
50. Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: A global surveillance report (2003-2004). J Antimicrob Chemother 2006; 57: 914-23.
51. Lewandowski T, Demarsh P, Peters T, Kulkarni, S. Potent Activity of GSK1322322 a novel peptide deformylase inhibitor after oral dosing in a murine multi-drug resistant Staphylococcus aureus infection. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference (Boston, MA), Poster F1-2113 (2010).
52. East SP, Ayscough A, Toogood-Johnson I, Taylor S, Thomas W. Peptidomimetic inhibitors of bacterial peptide deformylase. Bioorg Med Chem Lett 2011; 21: 4032-35.
53. Yu L, Zhou W, Wang Z. Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogs as peptide deformylase inhibitors. Bioorg Med Chem Lett 2011; 21: 1541-44.
54. Kang, J.H., Yu, S.W., Lee, H.Y., An, K.M., Cho, B.H. A new peptide deformylase inhibitor compound and manufacturing process thereof. US20100168421 (2010).
55. Sing, S.B., Wang, J., Basilio, A., Genilloud, O., Hernandez, P., Tormo, J.R. Antibiotic compound. WO2005009391A2 (2005).
56. Basilio, A., Genilloud, O., Jayasuriya, H., Gonzalez, I., Singh, S.B., Salazar, O., Wang, J. Antibiotic compound. WO2005115400A2 (2005).
57. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006; 441: 358-61.
58. Wang J, Kodali S, Kodali S, Galgoci A, Painter R, Dorso K, et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci USA 2007; 104: 7612-16.
59. Jayasuriya H, Herath KB, Zhang C, Zink DL, Basilio A, Genilloud O, et al. Isolation and structure of platencin: a novel FabH and FabF dual inhibitor with potent broad spectrum antibiotic activity produced by Streptomyces platensis MA7339. Angew Chem Int Ed 2007; 46: 4684-8.
60. Herath KB, Attygalle AB, Singh SB. Biosynthetic studies of platensimycin. J Am Chem Soc 2007; 129:15422-3.
61. Herath K, Attygalle AB, Singh SB. Biosynthetic studies of platencin. Tetrahedron Lett 2008; 49: 5755-8.
62. Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, Zhang C, Zink DL, et al. Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc 2006; 128:11916-20.
63. Singh SB, Young K. New antibiotic structures from fermentations Expert Opin Ther Pat 2010; 20:1359-71.
64. Phillips JW, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, et al. Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus Chem Biol 2011; 18: 955-65.
65. S. Tohyama, Y. Takahashi, Y. Akamatsu Biosynthesis of amycolamicin: the biosynthetic origin of a branched alpha-aminoethyl moiety in the unusual sugar amycolose. J Antibiot 2010; 63: 147-9.
66. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 2010, 54: 4636-42.
67. Macinga DR, Rather PN. The chromosomal 2'-N-acetyltrasnferase of Providencia stuartii: Physiological functions and genetic regulation. Front Biosci 1999; 4: D132-D140.
68. Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACH-490. Curr Opin Microbiol 2010; 13: 565-73.
69. Aggen, J.B., Linsell, M.S., Goldblum, A.A., Hildebrandt, D.J., Kane, T.R., Dozzo, P., Gliedt, M.J., Hanessian, S., Giguère, A., Grzyb, J., Mainati, J.P. Antibacterial aminoglycoside analogs. US20110275586 (2011).
70. Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob Agents Chemother 2010; 54: 2258-61.
71. Reyes N, Aggen JB, and Kostrub CF. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob Agents Chemother 2011; 55: 1728-33.
72. Armstrong, E.S., Bruss, J.B. Combination therapies using antibacterial aminoglycoside compounds US2010038138 (2010).
73. Leese, R.A., Francis, N., Curran, W.V., Orders, D.B., Jarolmen, H. Peptide antibiotics and peptide intermediates for their preparation. US2006004185 (2006).
74. Vaara, M., Vaara, T. Polymyxin derivatives and uses thereof. US7807637(2010).
75. Vaara M. New approaches in peptide antibiotics. Curr Opin Pharmacol 2009; 9: 571-6.
76. Vaara M. Polymyxins and their novel derivatives. Curr Opin Microbiol 2010,13: 574-81.
77. Walsh TR, Toleman MA. The emergence of pan-resistant Gramnegative pathogens merits a rapid global political response. J Antimicrob Chemother 2012; 67:1-3.
78. Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol 2010; 14: 347-61.
79. Baker CA, Farha MA and Brown ED. Chemical genomic approaches to study model microbes Chem Biol 2010; 17: 624-32.
80. Nichols RJ, Sen S, Choo YJ, Beltrao P, Zietek M, Chaba R, et al. Phenotypic landscape of a bacterial cell. Cell 2011; 144:143-56.
81. Donald, RGK, Skwish S, Forsyth RA, Anderson JW, Zhong T, Burns C, et al. A novel Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds. Chem Bio 2009; 16: 826-36.
82. Singh SB, Phillips JW, Wang J. Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing. Curr Opin Drug Discov Devel 2007; 10: 160-6.
83. Butler MS. The role of natural product chemistry in drug discovery. J Nat Prod 2004; 67: 2141-53.
84. Genilloud O, González I, Salazar O, Martín J, Tormo JR, Vicente F. Current approaches to exploit actinomycetes as a source of novel natural products. J Ind Microbiol Biotechnol 2011; 38; 375-89.
85. Rappé MS, Giovannoni SJ. The uncultured microbial majority. Annu Rev Microbiol 2003; 57: 369-94.
86. Piel J. Metabolites from symbiotic bacteria. Nat Prod Rep 2004; 21: 519-38.
87. Horinuchi S. Mining and polishing of the treasure trove in the bacterial genus Streptomyces. Biosci Biotechnol Biochem 2007; 71: 283-99.
88. Ryan RP, Dow JM. Diffusible signals and interspecies communication in bacteria. Microbiology 2008; 154: 1845-58.
89. Shank EA, Kolter R. New developments in microbial interspecies signaling. Curr Opin Microbiol 2009; 12: 205-14.
90. Winter JM, Behnken S, Hertweck C. Genomics-inspired discovery of natural products. Curr Opin Chem Biol 2011;15:22-31.
91. Singh BK, Macdonald CA. Drug discovery from uncultivable microorganisms Drug Discov Today 2010; 15: 792-99.
92. Lefevre F, Robe P, Jarrin C, Ginolhac A, Zago C, Auriol D, et al. Drugs from hidden bugs: their discovery via untapped resources. Res Microbiol 2008; 159: 153-61.
93. Miao V, Davies J Metagenomics and antibiotic discovery from uncultivated bacteria. In Uncultivated Microorganisms, Microbiology Monographs, S. S. Epstein Editor. Springer 2009; 10/2009: 161-80.
94. Kaeberlein T, Lewis K, Epstein SS. Isolating uncultivable microorganisms in pure culture in a simulated natural environment. Science 2002; 296: 1127-29.
95. Lewis K, Epstein S, D'Onofrio A, Ling LL. Uncultured microorganisms as a source of secondary metabolites. J Antibiotics 2010; 63: 468-76.
96. Gregory L. Challis Mining microbial genomes for new natural products and biosynthetic pathways Microbiology 2008; 154: 1555-69.
97. Nett M, Ikeda H, Moore BS. Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat Prod Rep 2009; 26: 1362-84.
98. Bentley SD, Chater KF, Cerdeño-Tárraga AM, Challis GL, Thomson NR, James KD, et al. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature 2002; 417: 141-7.
99. Bok JW, Noordermeer D, Kale SP, Keller NP. Secondary metabolic gene cluster silencing in Aspergillus nidulans. Mol Microbiol 2006; 61:1636-45.
100. Ikeda H, Ishikawa J, Hanamoto A, Shinose M, Kikuchi H, Shiba T, et al. Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis. Nat Biotechnol 2003; 21: 526-31.
101. Oliynyk M, Samborskyy M, Lester JB, Mironenko T, Scott N, Dickens S, et al. Complete genome sequence of the erythromycinproducing bacterium Saccharopolyspora erythraea NRRL23338. Nat Biotechnol 2007; 25: 447-53.
102. Omura S, Ikeda H, Ishikawa J, Hanamoto A, Takahashi C, Shinose M, et al. Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites. Proc Natl Acad Sci USA 2001; 98: 12215-20.
103. Machida M, Asai K, Sano M, Tanaka T, Kumagai T, Terai G, et al. Genome sequencing and analysis of Aspergillus oryzae. Nature 2005; 438:1157-61.
104. Udwary DW, Zeigler L, Asolkar RN, Singan V, Lapidus A, Fenical W, et al. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc Natl Acad Sci USA 2007; 104:10376-81.
105. Brakhage AA, Schroeckh V. Fungal secondary metabolites-Strategies to activate silent gene clusters. Fungal Genet Biol 2011; 48: 15-22.
106. Zerikly M, Challis GL. Strategies for the discovery of new natural products by genome mining. Chem Bio Chem 2009; 10: 625-63.
107. Corre C, Challis GL. New natural product biosynthetic chemistry discovered by genome mining. Nat Prod Rep 2009; 26: 977-86.
108. Bode HB, Bethe B, Höfs R, Zeeck A. 2002 Big effects from small changes: Possible ways to explore nature's chemical diversity. Chem Bio Chem 2002; 3: 619-27.
109. Scherlach K, Hertweck C. Triggering cryptic natural product biosynthesis in microorganisms Org Biomol Chem 2009; 7: 1753-60.
110. Ruiz B, Chavez A, Forero A, Garcia-Huante Y, Romero A, Sanchez M, et al. Production of microbial secondary metabolites: Regulation by the carbon source Crit Rev Microbiol 2010; 36: 146-67.
111. Martin JF. Phosphate control of the biosynthesis of antibiotics and other secondary metabolites is mediated by the PhoR-PhoP system: an unfinished story. J Bacteriol 2004; 186: 5197-201.
112. Hesketh A, Kock H, Mootien S Bibb M. The role of absC, a novel regulatory gene for secondary metabolism, in zinc-dependent antibiotic production in Streptomyces coelicolor A3(2). Mol Microbiol 2009; 74: 1427-44.
113. Hantke K. Iron and metal regulation in bacteria. Curr Opin Microbiol 2001; 4: 172-7.
114. Rigali S, Titgemeyer F, Barends S, Mulder S, Thomae AW, Hopwood DA, et al. Feast or famine: The global regulator DasR links nutrient stress to antibiotic production by Streptomyces. EMBO Rep 2008, 9: 670-5.
115. Bills GF, Platas G, Fillola A, Jimenez MR, Collado J, Vicente F, et al. Enhancement of antibiotic and secondary metabolite detection from filamentous fungi by growth on nutritional arrays J Appl Microbiol 2008; 104: 1644-58.
116. Goetz MA, Zhang C, Zink DL, Arocho M, Vicente F, Bills GF, et al. Coelomycin, a highly substituted 2,6-dioxo-pyrazine fungal metabolite antibacterial agent discovered by Staphylococcus aureus fitness test profiling. J Antibiot (Tokyo) 2010; 63:512-8.
117. Herath K, Jayasuriya H, Zink DL, Sigmund J, Vicente F, de la Cruz M, Basilio A, et al. Isolation, structure elucidation, and antibacterial activity of methiosetin, a tetramic acid from a tropical sooty mold (Capnodium sp.). J Nat Prod 2012; 75: 420-4.
118. Yamanaka K, Oikawa H, Ogawa H-O, Hosono K, Shinmachi F, Takano H, et al. Desferrioxamine E produced by Streptomyces griseus stimulates growth and development of Streptomyces tanashiensis. Microbiology 2005; 151: 2899-905.
119. Kawai K, Wang G, Okamoto S, Ochi K. The rare earth, scandium, causes antibiotic overproduction in Streptomyces sp. FEMS Microbiol Lett 2007; 274: 311-15.
120. van Wezel GP, McDowall KJ. The regulation of the secondary metabolism of Streptomyces: New links and experimental advances. Nat Prod Rep 2011; 28: 1311-33.
121. Nishida H, Ohnishi Y, Beppu T, Horinouchi D. Evolution of__butyrolactone synthases and receptors in Streptomyces. Environ Microbiol 2007; 9: 1986-94.
122. Corre C, Song LJ, O'Rourke S, Chater KF, Challis GL. 2-Alkyl-4-hydroxymethylfuran-3-carboxylic acids, a new class of antibiotic biosynthesis inducers discovered by Streptomyces coelicolor genome mining. Proc Natl Acad Sci USA 2008; 105: 17510-15.
123. Szeszak F, Vitalis S, Toth F, Valu G, Fachet J, Szabo G. Detection and determination of factor C-a regulatory protein-in Streptomyces strains by antiserum and monoclonal antibody. Arch Microbiol 1990; 154: 82-4.
124. Shwab EK, Bok JW, Tribus M, Galehr J, Graessle S, Keller NP. Histone deacetylase activity regulates chemical diversity in Aspergillus. Eukaryot Cell 2007; 6:1656-64.
125. Williams RB, Henrikson JC, Hoover AR, Lee AE, Cichewicz RH. Epigenetic remodeling of the fungal secondary metabolome. Org Biomol Chem 2008; 6:1895-97.
126. Henrikson JC, Hoover AR, Joyner PM, Cichewicz RH. A chemical epigenetics approach for engineering the in situ biosynthesis of a cryptic natural product from Aspergillus niger. Org Biomol Chem 2009; 7: 435-38.
127. de la Cruz M, Martín J, González-Menéndez V, Pérez-Victoria I, Moreno C, Tormo JR, et al. Chemical and physical modulation of antibiotic activity in Emericella species. Chem Biodivers 2012 (in press).
128. Ueda K, Kawai S, Ogawa HO, Kiyama A, Kubota T, Kawanobe H, et al. Wide distribution of interspecific stimulatory events on antibiotic production and sporulation among Streptomyces species. J Antibiot 2000; 53: 979-82.
129. Burgess JG, Jordan EM, Bregu M, Mearns-Spragg A, Boyd KG. Microbial antagonism: A neglected avenue of natural products research. J Biotechnol 1999; 70: 27-32.
130. Trischman JA, Oeffner RE, de Luna MG, Kazaoka M. Competitive induction and enhancement of índole and diketopiperazine in marine bacteria. Mar Biotechnol 2004; 6: 215-20.
131. Mearns-Spragg A, Bregu M, Boyd KG, Burgess JG. Cross-species induction and enhancement of antimicrobial activity produced by epibiotic bacteria from marine algae and invertebrates, after exposure to terrestrial bacteria. Lett Appl Microbiol 1998; 27: 142-6.
132. Onaka H, Mori Y, Igarashi Y, Furumai T. Mycolic acid-containing bacteria induce natural-product biosynthesis in Streptomyces species. Appl Environ Microbiol 2011; 77:400-406.
133. Pérez J, Muñoz-Dorado J, Braña AF, Shimkets LJ, Sevillano L, Santamaría RI. Myxococcus xanthus induces antinorhodin overproduction and aerial mycelium formation by Streptomyces coelicolor. Microb Biotechnol 2011; 4:175-83.
134. Schroeckh V, Scherlach K, Nützmann HW, Shelest E, Schmidt-Heck W, Schuemann J, et al. Intimate bacterial-fungal interaction triggers biosynthetic of archetypal polyketides in Aspergillus nidulans. Proc Nat Acad Sci USA 2009; 106: 14558-63.
135. Cueto M, Jensen PR, Kauffman C, Fenical W, Lobkovsky E, Clardy J. Pestalone, a new antibiotic produced by a marine fungus in response to bacterial challenge. J Nat Prod 2001; 64: 1444-46.
136. Oh DC, Jensen PR, Kauffman CA Fenical W. Libertellenones AD. Induction of cytotoxic diterpenoid biosynthesis by marine microbial competition. Bioorg Med Chem 2005; 13: 5267-73.
137. Oh DC, Kauffman CA, Jensen PR, Fenical W. Induced production of emericellamides A and B from the marine-derived fungus Emericella sp. in competing co-culture. J Nat Prod 2007; 70: 515-20.
138. Angell S, Bench BJ, Williams H, and Watanabe CM. Pyocyanin isolated from a marine microbial population: synergistic production between two distinct bacterial species and mode of action. Chem Biol 2006; 13: 1349-59.
139. Esquenazi E, Yang YL, Watrous J, Gerwick WH, Dorrestein PC. Imaging mass spectrometry of natural products Nat Prod Rep 2009; 26: 1521-34.
140. Watrous J, Hendricks N, Meehan M, Dorrestein PC, Capturing bacterial metabolic exchange using thin film desorption electrospray ionization-imaging mass spectrometry Anal Chem 2010; 82: 1598-1600.